[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530024":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":26,"id":53,"slug":26,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":26,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":26,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":26,"overallStatus":36,"whyStopped":26,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Rambam Health Care Campus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immediate oxytocin","EXPERIMENTAL","This arm will receive oxytocin when entering 2nd stage (full dilation)",[13],"Drug: Oxytocin",{"label":15,"type":6,"description":16,"interventionNames":17},"Delayed oxytocin","This arm will receive oxytocin one hour after entering 2nd stage (full dilation)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Oxytocin","Native oxytocin analog",[15,9],[25],"Pitocin",null,[28],{"name":29,"role":30,"phone":31,"phoneExt":26,"email":32},"Gal Bachar, MD","CONTACT","+97247771449","g_bachar@rambam.health.gov.il",[34],{"facility":35,"status":36,"city":37,"state":26,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Rambam medical health campus","RECRUITING","Haifa","31999","Israel","IL",{"type":42,"coordinates":43},"Point",[44,45],34.99928,32.81303,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":26,"phoneExt":26,"email":26},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Gal Bachar MD","Doctor of OBGYN","100530024",false,"NCT06181396","Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes","Association Between Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes","Inclusion Criteria:\n\n1. Singleton pregnancy\n2. Maternal age ≥ 18 years' old\n3. Oxytocin administration initiated or renewed during second stage of labor\n\nExclusion Criteria:\n\n1. Maternal age \\\u003C 18 years' old\n2. Multiple gestation pregnancy\n3. Known fetal malformations\n4. Uterine scar",true,"FEMALE","18 Years",{"count":63,"type":64},120,"ESTIMATED","INTERVENTIONAL",[67],"NA","Early oxytocin administration at the 2nd stage of labor is associated with a higher rate of vaginal delivery, shorter second stage duration, and fewer adverse maternal and neonatal outcomes.",[70,71],"Delivery Complication","Cesarean Delivery Affecting Fetus","2023-12-22",{"date":74,"type":75},"2023-12-26","ACTUAL",{"date":77,"type":75},"2023-10-01",{"date":79,"type":64},"2026-10",{"name":5,"class":6},1]